Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay

Clinical Biochemistry

Volumn 45, Issue 9, 2012, Pages 605-609

  Cotten, Steven W ^a   Duncan, Daniel L ^a   Burch, Elizabeth A ^b   Seashore, Carl J ^a   Hammett Stabler, Catherine A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Drugs of abuse; Interference; Meconium; Newborn; THC; Urine drug testing

Indexed keywords

CANNABINOID; SOAP; SURFACTANT;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG URINE LEVEL; FALSE POSITIVE RESULT; HUMAN; IMMUNOASSAY; INFANT; LABORATORY; NEWBORN; PRIORITY JOURNAL; SCREENING; URINALYSIS;

FALSE POSITIVE REACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; NEONATAL SCREENING; PSYCHOTROPIC DRUGS; SOAPS; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL;

EID: 84861232242     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.02.029     Document Type: Article

References (16)

1. Taylor P., Baily D., Peters R., et al. Substance abuse during pregnancy, guidelines for screening 2009, Washington State Department of Health. 2nd ed.
2. Havens J.R., Simmons L.A., Shannon L.M., et al. Factors associated with substance use during pregnancy: results from a national sample. Drug Alcohol Depend 2009, 99:89-95.
3. U.S. Department of Health and Human Services Results from the 2010 National Survey on Drug Use and Health: summary of national findings, Substance Abuse and Mental Health Services Administration; 2011. Report No.: SMA 11-4658 Available from. http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm.
4. Gareri J., Klein J., Koren G. Drugs of abuse testing in meconium. Clin Chim Acta 2006, 366:101-111.
5. Screening for illicit drug use: U.S. preventive services task force recommendation statement [cited 2011 Dec 28]. http://www.uspreventiveservicestaskforce.org/uspstf08/druguse/drugrs.htm.
6. Wong S., Ordean A., Kahan M. SOGC clinical practice guidelines: substance use in pregnancy: no. 256. Int J Gynaecol Obstet 2011, 114:190-202.
7. Yonkers K.A., Gotman N., Kershaw T., et al. Screening for prenatal substance use: development of the Substance Use Risk Profile - Pregnancy Scale. Obstet Gynecol 2010, 116:827-833.
8. Hammett-Stabler C.A., Pesce A., Cannon D. The medical use of urine drug screening. Clin Chim Acta 2002, 315:125-135.
9. Hammett-Stabler C.A., Bender L.M., Cotten S.W. Interference of prescriptive and over-the-counter medications with DAU immunoassays on the Vitros 5600. Clin Chem 2011, 57(S10):A76.
10. Baker D., Winecker R.E., Hammett-Stabler C.A. Cross-reactivity of sertraline, buprenorphine, buspirone, and bupropion with the Ortho drugs of abuse assays. Clin Chem 2010, 56(S6):A27.
11. Green K., Winecker R.E., Ives T.J., et al. Interference of the Roche drugs of abuse assay by tramadol. Clin Chem 2006, 52(S6):A63-A64.
12. VITROS Chemistry Products THC Reagent, version 6.0 2010, 1-15. Ortho Clinical Diagnostics, Inc.
13. Mikkelsen S.L., Ash K.O. Adulterants causing false negatives in illicit drug testing. Clin Chem 1988, 34:2333-2336.
14. Uebel R.A., Wium C.A. Toxicological screening for drugs of abuse in samples adulterated with household chemicals. S Afr Med J 2002, 92:547-549.
15. Warner A. Interference of common household chemicals in immunoassay methods for drugs of abuse. Clin Chem 1989, 35:648-651.
16. Child Welfare Information Gateway Parental drug use as child abuse [cited 2011 Dec 29]. Available from. http://www.childwelfare.gov/systemwide/laws_policies/statutes/drugexposed.cfm.